NexGel, Inc. (NXGL)

Over the past six months, NexGel, Inc.'s stock price has declined significantly and experienced volatility. In April 2026, NexGel received a Nasdaq deficiency letter for failing to meet the minimum bid price requirement. Also in April 2026, NexGel closed the acquisition of Celularity's regenerative biomaterial products, financed by a $5.5 million investment from Sequence LifeScience. Approximately five months prior to May 2026, NexGel announced the spin-off of select drug delivery application assets into NexGelRx. In November 2025, NexGel reported flat Q3 2025 revenue but improved gross margin. For the full year 2025, revenue increased by 31.5%, but the company reported a net loss and acknowledged doubt about its ability to continue as a going concern. In late April 2026, Ian Blackman was appointed as CFO, and in early May 2026, Brian Kieser and Kevin Harris from Sequence LifeScience were appointed to the Board of Directors.

The product line acquired from Celularity is seasonal, with the first quarter (Q1) generally being the weakest.

NexGel, Inc. is a biotechnology company specializing in advanced hydrogels for healthcare, consumer wellness, and cosmetics. They utilize an electron-beam cross-linking process to produce skin-friendly hydrogel formulations for various applications, including wound care and drug delivery. Major products include SilverSeal, MedaGel, Turfguard, Kenkoderm, Hexagels, and Silly George beauty products. They offer CDMO services through CG Converting & Packaging and are developing NEXDrape and NEXDerm. NexGel recently acquired regenerative biomaterial products from Celularity Inc., forming BioNX Surgical.

NexGel, Inc. is headquartered in Langhorne, Pennsylvania, with an FDA-registered and ISO-certified manufacturing facility. CG Converting and Packaging, LLC, is located in Granbury, Texas. The acquisition of Celularity's portfolio and partnership with Sequence LifeScience are expected to expand its commercial reach.

Information directly addressing NexGel's overall brand reputation in the past year is not explicitly detailed in the search results. The company has been described as a "Low-Profile Growth Company". The decline in stock price and Nasdaq deficiency letter could negatively impact investor perception. The acquisition of Celularity's regenerative biomaterial products and the partnership with Sequence LifeScience are expected to enhance the company's profile.

NexGel, Inc. has 21 institutional owners and shareholders holding a total of 591,896 shares. Major institutional owners include Vanguard Group Inc., Morgan Stanley, and Geode Capital Management, Llc. Individual insiders hold 14.4% of the company, while the general public holds 71.3%.